These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38081808)

  • 41. MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance.
    Mehlich D; Łomiak M; Sobiborowicz A; Mazan A; Dymerska D; Szewczyk ŁM; Mehlich A; Borowiec A; Prełowska MK; Gorczyński A; Jabłoński P; Iżycka-Świeszewska E; Nowis D; Marusiak AA
    Cell Death Dis; 2021 Nov; 12(12):1111. PubMed ID: 34839359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
    Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
    Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
    Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
    Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
    Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
    Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
    Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
    Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.
    Black JL; Harrell JC; Leisner TM; Fellmeth MJ; George SD; Reinhold D; Baker NM; Jones CD; Der CJ; Perou CM; Parise LV
    Breast Cancer Res Treat; 2015 Jul; 152(2):337-46. PubMed ID: 26105795
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
    Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
    J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer.
    Assidicky R; Tokat UM; Tarman IO; Saatci O; Ersan PG; Raza U; Ogul H; Riazalhosseini Y; Can T; Sahin O
    Breast Cancer Res Treat; 2022 Jun; 193(2):331-348. PubMed ID: 35338412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
    Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
    Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
    Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
    J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Oxygen-Generating Calcium Peroxide-Modified Magnetic Nanoparticles Attenuate Hypoxia-Induced Chemoresistance in Triple-Negative Breast Cancer.
    Cheng FY; Chan CH; Wang BJ; Yeh YL; Wang YJ; Chiu HW
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting the Id1-Kif11 Axis in Triple-Negative Breast Cancer Using Combination Therapy.
    Thankamony AP; Murali R; Karthikeyan N; Varghese BA; Teo WS; McFarland A; Roden DL; Holliday H; Konrad CV; Cazet A; Dodson E; Yang J; Baker LA; George JT; Levine H; Jolly MK; Swarbrick A; Nair R
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32911668
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tissue Inhibitor of Metalloproteinases-1 Overexpression Mediates Chemoresistance in Triple-Negative Breast Cancer Cells.
    Agnello L; d'Argenio A; Caliendo A; Nilo R; Zannetti A; Fedele M; Camorani S; Cerchia L
    Cells; 2023 Jul; 12(13):. PubMed ID: 37443843
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ST8SIA1 inhibition sensitizes triple negative breast cancer to chemotherapy via suppressing Wnt/β-catenin and FAK/Akt/mTOR.
    Wan H; Li Z; Wang H; Cai F; Wang L
    Clin Transl Oncol; 2021 Apr; 23(4):902-910. PubMed ID: 32939659
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer].
    Ma T; Zhang J; Wu J; Tang J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 May; 39(5):488-95. PubMed ID: 24921394
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
    Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
    J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.
    Cocco S; Leone A; Roca MS; Lombardi R; Piezzo M; Caputo R; Ciardiello C; Costantini S; Bruzzese F; Sisalli MJ; Budillon A; De Laurentiis M
    J Transl Med; 2022 Jun; 20(1):290. PubMed ID: 35761360
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy.
    He J; Lee HJ; Saha S; Ruan D; Guo H; Chan CH
    Cell Death Dis; 2019 Mar; 10(4):285. PubMed ID: 30918246
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dimethyl Fumarate Induces Apoptosis via Inhibition of NF-κB and Enhances the Effect of Paclitaxel and Adriamycin in Human TNBC Cells.
    Tsurushima K; Tsubaki M; Takeda T; Matsuda T; Kimura A; Takefuji H; Okada A; Sakamoto C; Ishizaka T; Nishida S
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955813
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability.
    Sirois I; Aguilar-Mahecha A; Lafleur J; Fowler E; Vu V; Scriver M; Buchanan M; Chabot C; Ramanathan A; Balachandran B; Légaré S; Przybytkowski E; Lan C; Krzemien U; Cavallone L; Aleynikova O; Ferrario C; Guilbert MC; Benlimame N; Saad A; Alaoui-Jamali M; Saragovi HU; Josephy S; O'Flanagan C; Hursting SD; Richard VR; Zahedi RP; Borchers CH; Bareke E; Nabavi S; Tonellato P; Roy JA; Robidoux A; Marcus EA; Mihalcioiu C; Majewski J; Basik M
    Mol Cancer Res; 2019 Dec; 17(12):2492-2507. PubMed ID: 31537618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.